ACADIA Pharmaceuticals Inc

ACAD remains in a Stage 2 markup, with medium-term bias bullish. The stock recently broke above key resistance and has pulled back into the rising EMA9, consolidating just above EMAs. Short-term conditions support buying this pullback for continuation toward prior highs while the long-term uptrend remains intact.

• ↑Q2 2026 revenue rose 17% YoY to $308 M, driven by 30% DAYBUE sales growth to $125 M.
• ↑Raised full-year 2026 revenue guidance to $1.24 B–$1.30 B on strong commercial momentum.
• ↓CFO sold $587 K in stock, raising insider confidence and governance concerns.